Literature DB >> 6165373

The presence of beta2 microglobulin on the membrane of the keratinocyte in premalignant skin disorders.

H R Vinninghe, H A Neumann.   

Abstract

Beta2 Microglobulin, the invariable light chain of the histocompatibility antigen, has proved to be absent on the cell surface of basal cell carcinoma. In actinically damaged skin and in patients with a past history of arsenic ingestion changes can be observed on the epidermal cell membrane which can predict malignancy before cell dysregulation is visible. The epidermis in the basal cell naevus syndrome behaves in this respect as normal epidermis and the spontaneous tumour growth cannot be explained by a predisposing defect in the HLA-antigens of the epidermal cell surface.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6165373     DOI: 10.1111/j.1365-2133.1981.tb08165.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Growth and antigenic characteristics of basal cell carcinoma in culture.

Authors:  M Bradbeer; A J Bourne; H Ayberk; S K Tang; R Marks
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

Review 2.  Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.

Authors:  Chrysoula I Liakou; Sowmita Narayanan; Derek Ng Tang; Christopher J Logothetis; Padmanee Sharma
Journal:  Cancer Immun       Date:  2007-06-26

3.  HLA class I antigen (heavy and light chain) expression by Langerhans cells and keratinocytes of the normal human epidermis: ultrastructural quantitation using immunogold labelling procedure.

Authors:  V Gielen; D Schmitt; J Thivolet
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

4.  Concanavalin-A binding sites, pemphigus antigens, and beta 2 microglobulin in epidermal hyperproliferation, premalignant and malignant lesions.

Authors:  G Mahrle; H Patyk; R Bolling
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.